about
Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN TrialEtravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.Impact of hepatitis C co-infection on response to antiretroviral treatment.Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trialAnalysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapyA comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected populationResearch letter: is monitoring for CD4 counts still needed for the management of patients with long-term HIV RNA suppression?Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
P50
Q30582633-071B7AAB-D8E1-4352-A4E5-C24665787596Q36013412-813CD226-BFE3-41EB-8EAE-A050D317EBCEQ37639881-20FC5122-BF35-4A99-85A3-2BEC83D32B40Q38013024-ACA7279E-3B3F-4495-99EE-2F2BBF8341FEQ38169902-E74E4244-EE46-42FF-BE98-5E663C424C2BQ41230514-BB7D1682-A9FA-4C6D-9BDD-90C42A3F5E1CQ42252552-449D05B0-353F-4A11-AA0F-64D7A34E6263Q42284769-626FB77C-5109-489D-8360-3CE4AE454F2DQ42927171-E7BAD5BA-CB6F-4344-8912-16C343EF9890Q43222175-6FB11C8F-1F23-4733-9A9E-299DEE90AE9CQ44257576-5C88E712-D54E-4718-9E33-F6045E2EAE8CQ44697091-C75EAAE8-3668-4F6D-9F87-52253813A1E5Q45015094-0A409CD6-BC7F-41B8-A41C-D3A8DF974DC3Q58000787-9A882206-36C5-4164-A38D-B0C1DC60C199Q58000813-A2E42DDB-BE93-4920-9AFC-CE7C79D78569Q82849742-78637AE0-2CA0-4B5D-A9FC-1FC63D88DACFQ85538182-2BD532B0-3632-40C9-8CD3-FE730EB28240Q92486817-4F9CAE95-E434-4BC6-B26D-ACB5ABFD6EEA
P50
description
researcher ORCID ID = 0000-0002-2965-6156
@en
wetenschapper
@nl
name
Yvon Van Delft
@ast
Yvon Van Delft
@en
Yvon Van Delft
@es
Yvon Van Delft
@nl
type
label
Yvon Van Delft
@ast
Yvon Van Delft
@en
Yvon Van Delft
@es
Yvon Van Delft
@nl
prefLabel
Yvon Van Delft
@ast
Yvon Van Delft
@en
Yvon Van Delft
@es
Yvon Van Delft
@nl
P106
P108
P31
P496
0000-0002-2965-6156